Acamprol: Clinically Proven Relief for Alcohol Dependence
| Product dosage: 333 mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.08 | $62.36 $62.36 (0%) | 🛒 Add to cart |
| 60 | $1.89 | $124.71 $113.65 (9%) | 🛒 Add to cart |
| 90 | $1.43 | $187.07 $128.74 (31%) | 🛒 Add to cart |
| 120 | $1.19 | $249.43 $142.82 (43%) | 🛒 Add to cart |
| 180 | $1.05
Best per pill | $374.14 $189.08 (49%) | 🛒 Add to cart |
Synonyms | |||
Acamprol (acamprosate calcium) is a prescription medication specifically formulated to support the maintenance of abstinence in alcohol-dependent patients who have achieved initial withdrawal and are committed to a comprehensive treatment program. It functions by helping to restore the natural balance of neurotransmitters in the brain, which are often disrupted by chronic alcohol use. By mitigating the neuronal hyperexcitability associated with alcohol withdrawal and craving, Acamprol provides a pharmacological foundation upon which behavioral therapy and counseling can build greater efficacy. Its delayed-release tablet formulation ensures consistent delivery of the active ingredient, supporting long-term therapeutic goals.
Features
- Active ingredient: Acamprosate calcium 333 mg
- Delayed-release enteric-coated tablets for optimal absorption
- Synthetic compound with structural similarity to gamma-aminobutyric acid (GABA)
- Renal excretion pathway with no significant hepatic metabolism
- Requires multiple daily dosing to maintain stable plasma concentrations
- Compatible with most comprehensive alcohol dependence treatment protocols
Benefits
- Reduces the frequency of relapse in patients with alcohol dependence
- Helps restore disrupted neurochemical balance in the central nervous system
- Decreases the intensity of post-acute withdrawal symptoms, particularly craving
- Supports long-term abstinence when combined with psychosocial interventions
- Demonstrates a favorable safety profile with minimal abuse potential
- Provides a non-dopaminergic mechanism of action distinct from other therapies
Common use
Acamprol is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is most effective when integrated into a comprehensive management program that includes psychosocial support, counseling, and treatment of comorbid conditions. The medication is typically initiated as soon as possible after the acute withdrawal period, once physical withdrawal symptoms have subsided. Treatment should be continued even if the patient experiences a lapse, as the medication remains effective in supporting return to abstinence.
Dosage and direction
The recommended dosage of Acamprol is two 333 mg tablets taken three times daily (total daily dose 1998 mg). For patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the dosage should be reduced to one 333 mg tablet three times daily. Treatment should be initiated as soon as possible after abstinence is achieved and maintained if the patient experiences a temporary relapse. Tablets should be swallowed whole with water and can be taken with or without food, though consistent administration with meals may improve gastrointestinal tolerance. The optimal duration of treatment has not been established, but clinical trials demonstrate efficacy for up to 52 weeks of continuous therapy.
Precautions
Patients should be monitored for the emergence of depression or suicidal ideation, as alcohol-dependent individuals constitute a high-risk population for these conditions. Renal function should be assessed before initiation and periodically during treatment, with dosage adjustment for patients with renal impairment. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing mothers should discontinue either nursing or the drug, taking into account the importance of the drug to the mother. Caution should be exercised when operating machinery or driving until the patient’s response to treatment is established.
Contraindications
Acamprol is contraindicated in patients with severe renal impairment (creatinine clearance ≤30 mL/min). It should not be administered to patients with known hypersensitivity to acamprosate calcium or any excipients in the formulation. The medication is not indicated for the promotion of abstinence in patients who have not undergone alcohol withdrawal or who continue to consume alcohol. Concomitant use with drugs that require renal clearance and have narrow therapeutic windows warrants careful consideration and monitoring.
Possible side effects
The most commonly reported adverse reactions include diarrhea (occurring in approximately 10-17% of patients), nausea, abdominal pain, pruritus, and various rash manifestations. These effects are generally mild to moderate in intensity and often diminish with continued treatment. Less frequently reported events include fluctuations in libido, dizziness, headache, and insomnia. Serious but rare adverse events include suicidal ideation and attempts, severe allergic reactions, and clinically significant electrolyte imbalances. Patients should be advised to report any persistent or bothersome symptoms to their healthcare provider.
Drug interaction
Formal drug interaction studies have shown no clinically significant interactions with diazepam, imipramine, haloperidol, or diazepam. However, given Acamprol’s renal elimination pathway, concomitant administration with drugs that affect renal function or are primarily renally excreted may require dosage adjustments. No pharmacokinetic interactions have been observed with disulfiram or antidepressants. Theoretical concerns exist regarding combined use with other centrally acting agents, though clinical significance remains uncertain. Healthcare providers should maintain awareness of all concomitant medications when prescribing Acamprol.
Missed dose
If a dose is missed, patients should take it as soon as they remember unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent adherence to the prescribed three-times-daily regimen is important for maintaining therapeutic plasma concentrations and optimal efficacy.
Overdose
Cases of overdose have been reported with doses up to 56 grams of acamprosate calcium. Symptoms may include gastrointestinal distress (diarrhea, nausea), dizziness, and electrolyte imbalances. No specific antidote exists, and treatment should consist of supportive measures with particular attention to hydration status and electrolyte balance. Hemodialysis may be considered in cases of significant overdose, especially in patients with renal impairment, as acamprosate is eliminated primarily by the kidneys.
Storage
Store at room temperature between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container with the lid tightly closed to protect from moisture. Do not transfer tablets to other containers. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly dispose of any unused medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Acamprol is available by prescription only and should be used under the supervision of a qualified healthcare professional. Individual response to treatment may vary, and not all patients will experience the same benefits. Patients should discuss their medical history, current medications, and treatment goals with their healthcare provider before initiating therapy. The full prescribing information should be consulted for complete details regarding use, warnings, and precautions.
Reviews
Clinical trials demonstrate that Acamprol significantly improves abstinence rates compared to placebo, with number needed to treat (NNT) values ranging from 8 to 12 for various outcome measures. Systematic reviews and meta-analyses consistently support its efficacy as part of a comprehensive treatment approach. Real-world evidence suggests that longer duration of therapy correlates with improved outcomes, particularly when combined with ongoing psychosocial support. Some patients report reduced craving within the first few weeks of treatment, though maximal benefits typically emerge after several months of consistent use. Healthcare providers generally regard Acamprol as a valuable component of alcohol dependence treatment, particularly for motivated patients engaged in comprehensive recovery programs.